

STATEMENT BY APPLICANT

(use as many sheets as necessary)

COMPLETE IF KNOWN**Application Number****Filing Date**

First Named Inventor

Group Art Unit

Examiner Name

Sheet

1

of

2

Attorney Docket Number

21500

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number	Kind Code (if known)		
A2		PCT	WO 96/15247		Merck & Co., Inc.	05/23/1996
		PCT	WO 98/34640		Merck & Co., Inc.	08/13/1998
		PCT	WO 99/02694		The University of Queensland	01/21/1999
		PCT	WO 01/14416 A2		Merck & Co., Inc.	03/01/2001
		PCT	WO 01/41799 A1		Epimune, Inc.	06/14/2001
		PCT	WO 02/08435 A1		Glaxo Group Limited	01/31/2002
		PCT	WO 03/077942 A2		GlaxoSmithKline Biologicals SA	09/25/2003
		PCT	WO 2004/084831 A2		Merck & Co., Inc.	10/07/2004

**Examiner
Signature**

Date
Considered

12/12/06


*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., -7/12/2005

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			COMPLETE IF KNOWN		
			Application Number	10/573330	
			Filing Date	1AP9 Rec'd PCT/PTO 24 MAR 2006	
			First Named Inventor	Bryan, et al.	
			Group Art Unit		
Examiner Name					
Attorney Docket Number	21500				
Sheet	2	of	2		

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
AJ		Bosch, et al., "Prevalence of Human Papillomavirus in Cervical Cancer: a Worldwide Perspective", J. Nat. Cancer Inst., Vol. 87, No. 11, June 7, 1995, pp. 796-802.
		Breitbart, et al., "Immunization with Viruslike Particles from Cottontail Rabbit Papillomavirus (CRPV) Can Protect Against Experimental CRPV Infection", J. of Virol., Vol. 69, No. 6, June 1995, pp. 3959-3963.
		Delius, et al., "Primer-Directed Sequencing of Human Papillomavirus Types", Curr. Topics in Microbiology and Immunology, Vol. 186, 1994, pp. 13-31.
		GenBank Accession No. Q9Y4Y5
		Kortula, et al., "Evaluation of Foreign Gene Codon Optimization in Yeast: Expression of a Mouse IG Kappa Chain", Bio/Technology, Vol. 9, December 1991, pp. 1386-1389.
		Liu, et al., "Polynucleotide viral vaccines: codon optimization and ubiquitin conjugation enhances prophylactic and therapeutic efficacy", Vaccine, Vol. 20, 2002, pp. 862-869.
		McMurray, et al., "Biology of human papillomaviruses", International Journal of Experimental Pathology, Vol. 82, 2001, pp. 15-33.
		Neeper, et al., "Expression of the major capsid protein of human papillomavirus type 11 in Saccharomyces cerevisiae", Gene, Vol. 180, 1996, pp. 1-6.
		Schiffman, et al., "Epidemiologic Evidence Showing That Human Papillomavirus Infection Causes Most Cervical Intraepithelial Neoplasia", Journal of National Cancer Institute, Vol. 85, No. 12, June 16, 1993, pp. 958-964.
		Schiller, et al., "Developing HPV virus-like particle vaccines to prevent cervical cancer: a progress report", Journal of Clinical Virology, Vol. 19, 2000, pp. 67-74.
		Schiller, et al., "Papillomavirus-Like Particles: Basic and Applied Studies", Papillomavirus Reviews: Current Research on Papillomaviruses, ed. Leeds, UK: Leeds Medical Information, 1996, pp. 101-112.
		Sharp, et al., "Synonymous Codon Usage in Saccharomyces cerevisiae", Yeast, Vol. 7, 1991, pp. 657-678.
		Suzich, et al., "Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomavirus", PNAS, Vol. 92, December 1995, pp. 11553-11557.
		Tobery, et al., "Effect of vaccine delivery system on the induction of HPV 16 L1-specific humoral and cell-mediated immune responses in immunized rhesus macaques", Vaccine, Vol. 21, 2003, pp. 1539-1547.
		Zhou, et al., "Papillomavirus Capsid Protein Expression Level Depends on the Match between Codon Usage and tRNA Availability", J. of Virol., Vol. 73, No. 6, June 1999, pp. 4972-4982.

Examiner Signature		Date Considered	12/12/06
--------------------	---	-----------------	----------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., -7/12/2005